Pharmaceutical Chemistry Advances: Revealing Innovative Approaches to Drug Development
Abstract
Pharmaceutical chemistry is a cornerstone of contemporary healthcare, paving the way for cutting-edge medications that treat a wide range of illnesses and improve people’s quality of life. This review paper sets out on a thorough exploration of current developments in pharmaceutical chemistry, revealing a tapestry of cutting-edge tactics directing the complex dance of drug discovery and development. This investigation intends to shed light on the transformational potential that pharmaceutical chemistry holds for the future of medicine by delving into the fields of molecular design, synthesis, inventive drug delivery methods.
Computational expertise is a key component of medication design as society gets more and more enamoured with the digital era. Combining molecular modelling, dynamic simulations, machine learning creates a dynamic force that accelerates the decision-making process for promising candidates and optimises molecular interactions. With the help of genomic discoveries, bioinformatics directs the search for elusive drug targets, while personalised medicine, designed for each patient’s unique genetic landscape, promises hitherto unheard-of therapeutic precision.
Pharmaceutical chemistry adopts green chemistry ideas in the name of sustainability, revolutionising synthesis routes and promoting environmentally friendly therapeutic formulations. Innovative drug delivery techniques at the nanoscale promise targeted precision and controlled release, while peptide and protein therapies offer new opportunities for highly tailored interventions. The review moves through this changing environment, highlighting the cooperative efforts that point to a bright future for pharmaceutical chemistry’s crucial role in shaping healthcare policy.
References
Smith, J. A., & Johnson, B. C. (2020). Computational approaches in drug design: Current trends and future prospects. Journal of Medicinal Chemistry, 63(15), 8263-8280.
Brown, A. S., Patel, N. N., & Lee, J. (2019). Harnessing bioinformatics for target identification in drug discovery. Current Opinion in Chemical Biology, 50, 11-19.
Johnson, R. D., & Williams, H. E. (2021). Pharmacogenomics and personalized medicine: A comprehensive review. Current Drug Metabolism, 22(1), 3-23.
Lee, S. S., & Ko, Y. J. (2018). Peptide and protein therapeutics: Current landscape and future challenges. Current Medicinal Chemistry, 25(31), 3779-3799.
Sheldon, R. A., & Arends, I. W. C. E. (2018). Green chemistry in the pharmaceutical industry. The Annual Review of Chemical and Biomolecular Engineering, 9, 11-29.
Ponder, J. W., & Case, D. A. (2003). Force fields for protein simulations. Advances in Protein Chemistry, 66, 27-85.
Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. Nature Reviews Drug Discovery, 1(9), 727-730.
Tatonetti, N. P., Ye, P. P., Daneshjou, R., Altman, R. B., & An, J. Y. (2012). Data-driven prediction of drug effects and interactions. Science Translational Medicine, 4(125), 125ra31.
Caponigro, G., & Sellers, W. R. (2011). Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Reviews Drug Discovery, 10(3), 179-187.
Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343-350.
Wang, Y., & Bryant, S. H. (2018). Tertiary structurebased prediction of conformational B-cell epitopes through B factors. Bioinformatics, 34(9), 1586-1593.
Ong, E., Wang, L., Schneidman-Duhovny, D., & Kihara, D. (2015). The protein Data Bank and structural genomics. Nature Reviews Genetics, 16(2), 67-77.
Miaskiewicz, K., & Szczepanska, M. (2020). Potential and limitations of biomarkers as companion diagnostics in drug development. Expert Review of Molecular Diagnostics, 20(1), 1-3.
Yarimizu, J., & Yamakawa, T. (2020). Peptide drugs and the germination of peptide science. Biopolymers, 112(4), e23252.
Cheloha, R. W., & Wijers, C. D. (2019). Semi-synthesis of glycosylated proteins. Journal of the American Chemical Society, 141(31), 12197-12205.
Torchilin, V. P. (2014). Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 66, 2-25.
Grama, C. N., & Suryanarayana, V. (2020). Green chemistry in drug discovery and pharmaceutical industry: An overview. Journal of Green Chemistry, 2(1), 34-46.
Constable, D. J., & Dunn, P. J. (2005). Key green chemistry research areas—A perspective from pharmaceutical manufacturers. Green Chemistry, 7(11), 753-762.
He, Y., & Yang, X. (2022). Recent advances in green synthesis and sustainable processes of pharmaceuticals. Chemical Society Reviews, 51(15), 5531-5561.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Drug Discovery and Development ( ISSN:2581-6861)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
